ArticleScientific reports2018
E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium.
Abstract read
In one paragraph
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Metabolic maintenance of breast cancer cells and metastases through E-cadherin/YAP-dependent pyruvate carboxylase expression.bioRxiv : the preprint server for biology · 2026Article
- Topology-Based Biomarkers Accurately Predict Breast Cancer Outcome and Survival.Cancer research · 2026Article
- Multi-Protein Profiling Reveals High Nuclear KFL-4 Expression as a Predictor of Poor Overall Survival in Breast Cancer: A Retrospective Cohort Study.International journal of molecular sciences · 2026Article
- 3D "Emboli" Culture Models Epithelial Breast Cancer Cell Oxidative Mitochondrial Metabolism with Relevance for Lung Metastasis.Cancer research communications · 2026Article
- Development of novel anti-CDH1/E-cadherin monoclonal antibodies for versatile applications.Biochemistry and biophysics reports · 2026Article
- Distinct transcriptomic features of tumor and stromal cells in direct contact in luminal and triple-negative breast cancers.Exploration of targeted anti-tumor therapy · 2026Article
- Diagnostic dilemma of lobular carcinoma: a mini-review of imaging modalities and the role of artificial intelligence and radiomics.Frontiers in oncology · 2025Review
- Targeted Inhibition of p21 Promotes the Growth of Breast Cancer Cells and Impairs the Tumor-Killing Effect of the Vaccinia Virus.Journal of breast cancer · 2024Article
- Expression of E-Cadherin and N-Cadherin in the Endocervix as a Predictive Factor in Patients with Endometrial Cancer.International journal of molecular sciences · 2024Article
- Unravelling heterogeneous effects of cancer‑associated fibroblasts on poor prognosis markers in breast cancer EM‑G3 cell line:Oncology reports · 2024Article
- Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer.JCI insight · 2023Article
- Polygenic risk scores and breast cancer risk prediction.Breast (Edinburgh, Scotland) · 2023Review
- Role of TNFSF15 variants in oral cancer development and clinicopathologic characteristics.Journal of cellular and molecular medicine · 2022Article
- Review
- Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistance.Genome medicine · 2022Article
- Radiobiological effects of wound fluid on breast cancer cell lines and human-derived tumor spheroids in 2D and microfluidic culture.Scientific reports · 2022Article
- Article
- Comparison of Fixation Methods for the Detection of Claudin 1 and E-Cadherin in Breast Cancer Cell Lines by Immunofluorescence.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022Article
- Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications.Journal of pathology informatics · 2022Article
- Review
Corrections and comments
- Commented on by
Authors and funding
52 authors.
Hisani N HorneDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Hannah OhDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Mark E ShermanHealth Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
Maya PalakalDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Stephen M HewittCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Marjanka K SchmidtDivision of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Roger L MilneCancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia.ORCID 0000-0001-5764-7268
David HardissonDepartment of Pathology, Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz IdiPAZ, and Facultad de Medicina, Universidad Autonoma de Madrid, Madrid, Spain.ORCID 0000-0002-2183-3699
Javier BenitezHuman Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid, Spain.
Carl BlomqvistDepartment of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Manjeet K BollaCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Renata CoraIndependent contractor, CT(ASCP), MB (ASCP), National Cancer Institute, Bethesda, MD, USA.
Fergus J CouchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Katarina CukDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Peter DevileeDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.ORCID 0000-0003-2444-3247
Diana M EcclesCancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
Ursula EilberDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jaana M HartikainenTranslational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.
Päivi HeikkiläDepartment of Pathology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Bernd HolleczekSaarland Cancer Registry, Saarbrücken, Germany.
Maartje J HooningDepartment of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Michael JonesDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Renske KeemanDivision of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Arto MannermaaTranslational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.
John W M MartensDepartment of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID 0000-0002-3428-3366
Taru A MuranenDepartment of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Heli NevanlinnaDepartment of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-0916-2976
Janet E OlsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Nick OrrThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Jose I A PerezServicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain.
Paul D P PharoahCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.ORCID 0000-0001-8494-732X
Kathryn J RuddyDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Kai-Uwe SaumDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Minouk J SchoemakerDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Caroline SeynaeveDepartment of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Reijo SironenTranslational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.
Vincent T H B M SmitDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Anthony J SwerdlowDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Maria TengströmTranslational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.
Abigail S ThomasDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
A Mieke TimmermansDepartment of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Rob A E M TollenaarDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Melissa A TroesterDepartment of Pathology and Laboratory Medicin, Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Christi J van AsperenDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Carolien H M van DeurzenDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Flora F Van LeeuwenDivision of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Laura J Van't VeerDivision of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Montserrat García-ClosasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Jonine D FigueroaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. Jonine.figueroa@ed.ac.uk.ORCID 0000-0002-5100-623X
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MHormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5MThe Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2005 to 2026
$49.9MMayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2MZESTRIL VS. VERAPAMIL IN THE TREATMENT OF HYPERTENSIONM01RR000585 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 1985 to 2006
$30.4MExperimental Pathology Laboratory (EPL)ZICBC011638 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HEWITT, STEPHEN · 2015 to 2025
$16.6MInstitutional Career Development CoreKL2TR002379 · NCATS · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2017 to 2026
$14.9MMayo Clinic Center for Translational Science ActivitiesKL2TR000136 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$6.6MRisk and penetrance of mutations from breast cancer testing panels.R01CA192393 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH, NATHANSON, KATHERINE L. · 2014 to 2018
$6.3MIdentifying and validating novel susceptibility genes for breast cancerR01CA176785 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH, NATHANSON, KATHERINE L. · 2014 to 2018
$3.4MBRCA2 missense mutations and breast cancerR01CA116167 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2007 to 2011
$3.0MBRCA1 and BRCA2 missense mutations and breast cancer riskU01CA116167 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2013 to 2017
$2.7MCancer Research UK 10118Cancer Research UK 16563Cancer Research UK 19187Cancer Research UK C1275/A11699Cancer Research UK C1275/A15956Cancer Research UK C1275/A19187Cancer Research UK C1275/C22524Cancer Research UK C1287/A10118Cancer Research UK C1287/A16563NCATS NIH HHS KL2 TR000136NCATS NIH HHS KL2 TR002379NCATS NIH HHS UL1 TR000135NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA116167NCI NIH HHS R01 CA176785NCI NIH HHS R01 CA192393NCI NIH HHS U01 CA116167NCRR NIH HHS M01 RR000585
Abstract
E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, >2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97-1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06-2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes.
Indexed as
Gene ExpressionAdultAgedBiomarkers, TumorBreast NeoplasmsCadherinsCase-Control StudiesErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedOdds RatioPrognosisProportional Hazards ModelsReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorCadherinsErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.